According to the HPV Information Centre, the global prevalence of Human Papillomavirus (HPV) infection in women is approximately 11-12%. The highest prevalence is in regions like sub-Saharan Africa (24%), Eastern Europe (21%) and Latin America (16%). Common medications given to manage the disease include salicylic acid, imiquimod, and trichloroacetic acid among others. Several clinical trials are ongoing to develop innovative human papillomavirus (HPV) therapies to improve and manage the condition including vaccines.
The Human Papillomavirus (HPV) Pipeline Report by Expert Market Research gives comprehensive insights into human papillomavirus (HPV) therapeutic products currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Human Papillomavirus (HPV). The human papillomavirus (HPV) pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Human Papillomavirus (HPV).
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing human papillomavirus (HPV) development activities related to Human Papillomavirus (HPV) are covered.
Human papillomavirus is a viral infection which commonly causes skin or mucous membrane growths. There are several varieties of human papillomavirus. Some types of infection cause warts and some cause different types of cancer. Generally, human papillomavirus infections don't lead to cancer, but some are linked to causing uterine cancer. Other cancers linked to human papillomavirus infection include anus, vagina, penis, vulva and back of the throat. The symptoms depend on the type of human papillomavirus type, which includes genital warts, common warts, plantar warts, and flat warts.
The medications for human papillomavirus infection are used to eliminate warts and are applied directly to the lesion. It includes salicylic acid, imiquimod, podofilox, trichloroacetic acid. Over-the-counter treatments include salicylic acids which work by removing layers of a wart. On the other hand, Imiquimod is a prescription cream and it is used to enhance the immune system's ability to fight human papillomavirus infection. Podofilox is another topical prescription which works by destroying genital wart tissue and trichloroacetic acid is a chemical treatment which burns off warts on the soles, palms, and genitals. Clinical trials for human papillomavirus therapeutics are focusing on several aspects. Merck announced the clinical development of a new investigational multi-valent human papillomavirus vaccine. It is designed to provide broader protection against multiple types of human papillomavirus. Additionally, Merck also plans to conduct clinical trials to assess the safety of a single-dose regimen of GARDASIL®9 in both males and females. The increased number of drugs clinical trials for human papillomavirus has impacted the human papillomavirus (HPV) pipeline landscape significantly.
This section of the report covers the analysis of human papillomavirus (HPV) emerging drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s human papillomavirus (HPV) therapeutic assessment covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s human papillomavirus (HPV) clinical assessment covers 50+ drug analyses based on the route of administration.
The human papillomavirus (HPV) report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for human papillomavirus.
The drug molecules categories covered under the human papillomavirus (HPV) pipeline analysis include small molecule, gene therapy, cell therapy, and immunotherapy. Several studies are investigating T-cell therapies for the treatment of metastatic human papillomavirus infection-associated epithelial cancers. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus (HPV).
The EMR human papillomavirus (HPV) report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Human Papillomavirus (HPV) clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and human papillomavirus (HPV) therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming human papillomavirus (HPV) drug candidates.
The trial is designed to evaluate the immunogenicity of GSK Biologicals' HPV-16/18 L1 AS04 vaccine in female patients who are enrolled from multiple countries in Africa. The trial is sponsored by GlaxoSmithKline and is currently under phase III.
The objective of the study is to evaluate the safety of human papillomavirus DNA Plasmid (VGX-3100) in adult females previously immunized with VGX-3100. The trial is sponsored by Inovio Pharmaceuticals and is currently under phase I.
Merck Sharp & Dohme LLC is developing this human papillomavirus (HPV) drug candidate and is currently under phase III. The study is being conducted to evaluate the efficacy of a multivalent human papillomavirus L1 Virus-Like Particle (VLP) Vaccine. It is being administered to preadolescents and adolescents.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Human Papillomavirus (HPV) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus (HPV). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within human papillomavirus (HPV) pipeline insights.
Global Human Papillomavirus (HPV) Vaccine Market
Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share